Serum caffeine concentrations in preterm neonates

被引:43
作者
Concha Leon, Alonso E.
Michienzi, Kelly
Ma, Chang-Xing
Hutchison, Alastair A.
机构
[1] Women & Childrens Hosp Buffalo, Dept Pediat, Div Neonatol, Buffalo, NY 14222 USA
[2] Women & Childrens Hosp, Dept Pharm, Buffalo, NY USA
[3] SUNY Buffalo, Dept Biostat, New York, NY USA
关键词
serum caffeine concentrations; preterm neonates;
D O I
10.1055/s-2006-958163
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Caffeine therapy reduces apnea of prematurity, promotes successful extubation from invasive positive-pressure ventilation, and decreases the incidence of bronchopulmonary dysplasia. The recommended dosing for caffeine is a loading dose of 20 mg/kg followed by a 5 mg/kg/d maintenance dose. However, controversy exists about the optimal dosing regimen and data on serum caffeine concentrations in extremely immature infants are scant. We determined serum caffeine concentrations similar to 7 days after starting therapy with a 20 or 25 mg/kg loading dose and a 6 mg/kg/d maintenance dose in 154 infants with a mean gestational age of 29 weeks. The 25th to 75th percentile range for the serum caffeine concentrations with the two dosing regimens was equivalent, similar to 18 to 23 mg/L. Within the first 14 postnatal days, the serum caffeine concentrations were not dependent on postmenstrual age, weight, or postnatal age, and were in a range that is safe and therapeutic. This latter observation remained valid over the ranges of clinical and laboratory assessments of renal and hepatic functions that are usually found in practice. Routine measurement of steady-state serum caffeine concentrations in infants 24 to 35 weeks gestational age is not required in the absence of ongoing apnea/hypopnea or signs compatible with toxicity.
引用
收藏
页码:39 / 47
页数:9
相关论文
共 20 条
[1]   Caffeine metabolism in premature infants [J].
Al-Alaiyan, S ;
Al-Rawithi, S ;
Raines, D ;
Yusuf, A ;
Legayada, E ;
Shoukri, MM ;
El-Yazigi, A .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (06) :620-627
[2]   PHARMACOKINETIC PROFILE OF CAFFEINE IN THE PREMATURE NEWBORN-INFANT WITH APNEA [J].
ARANDA, JV ;
COOK, CE ;
GORMAN, W ;
COLLINGE, JM ;
LOUGHNAN, PM ;
OUTERBRIDGE, EW ;
ALDRIDGE, A ;
NEIMS, AH .
JOURNAL OF PEDIATRICS, 1979, 94 (04) :663-668
[3]   MATURATION OF CAFFEINE METABOLIC PATHWAYS IN INFANCY [J].
CARRIER, O ;
PONS, G ;
REY, E ;
RICHARD, MO ;
MORAN, C ;
BADOUAL, J ;
OLIVE, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (02) :145-151
[4]   Caffeine citrate: A review of its use in apnoea of prematurity [J].
Comer A.M. ;
Perry C.M. ;
Figgitt D.P. .
Paediatric Drugs, 2001, 3 (1) :61-79
[5]   Drugs for treatment of very high blood pressure during pregnancy [J].
Duley, Lelia ;
Meher, Shireen ;
Jones, Leanne .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (07)
[6]   Caffeine citrate for the treatment of apnea of prematurity: A double-blind, placebo-controlled study [J].
Erenberg, A ;
Leff, RD ;
Haack, DG ;
Mosdell, KW ;
Hicks, GM ;
Wynne, BA .
PHARMACOTHERAPY, 2000, 20 (06) :644-652
[7]   Summary proceedings from the apnea-of-prematurity group [J].
Finer, NN ;
Higgins, R ;
Kattwinkel, J ;
Martin, RJ .
PEDIATRICS, 2006, 117 (03) :S47-S51
[8]   EFFECT OF FORMULA FEEDING ON ORAL ABSORPTION OF CAFFEINE IN PREMATURE-INFANTS [J].
GIACOIA, GP ;
JUNGBLUTH, GL ;
JUSKO, WJ .
DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1989, 12 (04) :205-210
[9]   PHARMACOKINETIC ASPECTS OF CAFFEINE IN PREMATURE-INFANTS WITH APNEA [J].
GORODISCHER, R ;
KARPLUS, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (01) :47-52
[10]   SEQUELAE OF CAFFEINE TREATMENT IN PRETERM INFANTS WITH APNEA [J].
GUNN, TR ;
METRAKOS, K ;
RILEY, P ;
WILLIS, D ;
ARANDA, JV .
JOURNAL OF PEDIATRICS, 1979, 94 (01) :106-109